Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial
Phospholipovit significantly reduced non-HDL-C, TG, and atherogenic lipoproteins in patients with combined hyperlipidemia and moderate cardiovascular risk. It can be used as an add-on therapy to statins.
Authors
- В. В. Кухарчук (ORCID: https://orcid.org/0000-0002-7028-362X)
- Andrey Lisitsa (ORCID: https://orcid.org/0000-0003-2852-102X)
- Yulia Romashova
- Vladimir Aleksandrovich Kutsenko (ORCID: https://orcid.org/0000-0001-9844-3122)
- O. M. Ipatova (ORCID: https://orcid.org/0000-0001-6285-1669)
- С. С. Маркин (ORCID: https://orcid.org/0000-0002-0242-0282)
- E.G. Tikhonova
- Е. B. Yarovaya (ORCID: https://orcid.org/0000-0002-6615-4315)
- В. В. Береговых (ORCID: https://orcid.org/0000-0002-0210-4570)
- С. А. Иванов (ORCID: https://orcid.org/0000-0001-7689-6032)
- M. Zubareva (ORCID: https://orcid.org/0000-0002-2980-9167)
- Elena A. Ponomarenko (ORCID: https://orcid.org/0000-0001-8527-6003)
- M. I. Guseva
- F.N. Bedretdinov
- Аlexander Archakov
- Tatiana O. Pleshakova (ORCID: https://orcid.org/0000-0002-5435-5937)
Institutions
- Lomonosov Moscow State University (RU)
- National Medical Research Center of Cardiology (RU)
- Institute of Biomedical Chemistry (RU)
Publication Details
- Journal
- Research in Pharmaceutical Sciences
- Published
- 2024-11-01
- DOI
- https://doi.org/10.4103/rps.rps_274_23
- Citations
- 4
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Ministry of Science and Higher Education of the Russian Federation